Welcome to our dedicated page for Haoxi Health Technology news (Ticker: HAO), a resource for investors and traders seeking the latest updates and insights on Haoxi Health Technology stock.
Haoxi Health Technology Limited (HAO) is a prominent online marketing solution provider headquartered in Beijing, China. Specializing in the healthcare industry, Haoxi delivers comprehensive marketing strategies to help advertisers in acquiring, converting, and retaining consumers through a variety of digital platforms.
Core to Haoxi's business is the provision of one-stop online marketing solutions, particularly focusing on short video marketing. By collaborating with major media partners, Haoxi customizes, plans, produces, places, and optimizes online ads. This approach ensures that advertisers can achieve their marketing goals on popular Chinese social media platforms such as Douyin, Toutiao, WeChat, and Sina Weibo.
Haoxi has recently made significant strides, including entering into a Framework Contract with Wuhan Yiya Simei Dental Clinic Co., Ltd., a regional dentistry chain in China. This partnership involves providing targeted advertising services across multiple social media platforms, catering to a diverse audience through short-video, text, images, and mobile app content formats. The contract is valued at a minimum of RMB 40 million ($5.5 million), highlighting Haoxi's capability to deliver high-value marketing solutions.
In another notable development, Haoxi signed a Rebate Agreement with Jinan Yanling Biotechnology Co., Ltd., setting a target advertising spend of at least RMB 50 million ($7 million). This agreement leverages ByteDance's extensive advertising platforms, such as Jinri Toutiao and Xigua Video, to enhance the promotional efforts of Yanling and its affiliated entities in the biomedical and health technology sectors.
With a commitment to leveraging robust data analysis tools for real-time monitoring and optimization, Haoxi ensures that advertising efforts are efficient and impactful. The company remains focused on reducing costs, increasing efficiency, and providing user-friendly marketing solutions, aiming for sustainable business growth and enhanced client satisfaction.
For more information, please visit: http://ir.haoximedia.com
Haoxi Health Technology (HAO) announced that its subsidiary Beijing Haoxi Digital Technology has secured a RMB30 million Framework Contract to provide digital advertising services for Tengyuan Media Advertising and its clients. Under the agreement, Beijing Haoxi will deliver customized internet marketing services through its media platform network over the next year. The company will utilize its marketing expertise to enhance competitiveness for Tengyuan and its clients. The partnership is described as a strategic milestone that aims to strengthen HAO's service capabilities and market position in the digital marketing industry.
Haoxi Health Technology (HAO) received a notification from Nasdaq on October 31, 2024, regarding non-compliance with the minimum bid price requirement. The company's stock failed to maintain the required $1.00 minimum bid price for 30 consecutive business days from September 19 to October 30, 2024. HAO has been granted 180 calendar days, until April 25, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. If unsuccessful, the company may face delisting, though it may be eligible for additional time. HAO is considering options including a potential reverse share split to meet requirements.
Haoxi Health Technology (HAO) reported strong financial results for fiscal year 2024. Net revenue increased 72% to $48.52 million, up from $28.23 million in 2023. Gross profit rose 33% to $2.75 million, while net income grew 33% to $1.29 million. The company expanded its customer base from 393 to 543 clients, with average revenue per client increasing from $71,830 to $89,355. HAO's cash position strengthened to $6.66 million from $1.20 million year-over-year. The company recently closed a $12 million follow-on offering and announced a strategic partnership with AI platform Gauss Intelligence.
Haoxi Health Technology (HAO), an online marketing solution provider in Beijing, China, has announced preliminary unaudited financial results for FY24 ended June 30, 2024. The company projects 72% revenue growth to approximately $48.52 million, up from $28.23 million in FY23. Gross profit is expected to increase by 33.4% to $2.75 million, while net income is projected to rise 33.2% to $1.29 million.
HAO attributes this growth to its strategic development in online advertising solutions, particularly through short video formats and news feed ads. The company's proprietary data analysis software, Bidding Compass, has reportedly optimized ad placements, driving revenue and profit growth. Total assets increased to $15.51 million from $4.46 million at the end of FY23, reflecting operational scale and capital utilization post-IPO in January 2024.
Haoxi Health Technology (HAO) has announced a strategic partnership with Global Mofy AI 's subsidiary, Gauss Intelligence (Beijing) Technology Co., The collaboration aims to integrate Gausspeed, an advanced generative AI platform, with HAO's extensive application scenarios to create innovative AI marketing solutions.
The partnership will focus on three key areas: enhancing big data analysis, automating creative content generation, and improving intelligent decision-making processes. Global Mofy, a leading digital asset bank in China managing over 100,000 digital assets, will provide AI capabilities through Gausspeed. HAO will contribute its industry knowledge and practical application expertise.
Gausspeed, launched in 2024, uses Physics AI to simulate intelligent behavior, build and navigate complex 3D environments, and enable sophisticated interactions among digital assets. This collaboration is expected to revolutionize digital marketing approaches and drive digital transformation across the marketing landscape.
Haoxi Health Technology (HAO), an online marketing solution provider based in Beijing, has successfully closed its previously announced underwritten follow-on public offering. The company raised $12 million by offering 4,000,000 units at a price of $3.00 per unit. Each unit consists of one Class A Ordinary Share (or pre-funded warrant), one Series A warrant, and one Series B warrant.
The offering was conducted on a firm commitment basis, with EF Hutton acting as the sole bookrunner. HAO has granted EF Hutton a 45-day option to purchase up to an additional 600,000 units to cover over-allotments. The company plans to use the proceeds for business expansion and technology investments in the healthcare industry.
Haoxi Health Technology (HAO), an online marketing solution provider based in Beijing, has announced the pricing of its underwritten follow-on public offering. The company is offering 4,000,000 units at $3.00 per unit, aiming to raise $12 million in gross proceeds. Each unit consists of one Class A Ordinary Share (or a pre-funded warrant), one Series A warrant, and one Series B warrant to purchase Class A Ordinary Shares. The warrants have a 5-year term with varying exercise prices and conditions. EF Hutton is acting as the sole bookrunner for the offering, which is expected to close around September 20, 2024. HAO plans to use the proceeds for working capital, general corporate purposes, potential acquisitions, and hiring.
Haoxi Health Technology (HAO), based in Beijing, China, has announced a strategic initiative to support international humanitarian aid amid global challenges. The company, known for its digital marketing solutions, is leveraging its resources to address urgent medical supply needs in crisis-hit regions. HAO has formed a dedicated service team to collaborate with international medical aid organizations, sourcing essential items such as medical equipment, pharmaceuticals, and protective gear. Chairman and CEO Zhen Fan emphasizes the importance of corporate social responsibility and invites other companies and individuals to join their efforts to alleviate global humanitarian crises.
Haoxi Health Technology (HAO) reported its unaudited financial results for the six months ended December 31, 2023. The company recorded a significant increase in total revenue, reaching $23.50 million, a 157% rise from $9.16 million in the same period of 2022.
Gross profit rose by 65% to $1.20 million, while net income increased by 70% to $0.76 million. HAO's growth was driven by an increase in the number of clients served, from 183 to 338, and a higher average revenue per client, primarily from the healthcare sector.
Recent developments include partnerships with Wuhan Yiya Simei Dental Clinic and Jinan Yanling Biotechnology, focusing on delivering comprehensive advertising services on popular social media platforms. However, the company's gross margin decreased due to market competition, leading to higher costs and required customer rebates.
Haoxi Health Technology announced a Rebate Agreement with Jinan Yanling Biotechnology Co., for comprehensive advertising and promotion services in the health-related industries. The agreement includes a targeted advertising spend of at least RMB50 million on ByteDance's platforms. This partnership aims to enhance brand exposure, image, and market reach for Yanling and its affiliates.
FAQ
What is the current stock price of Haoxi Health Technology (HAO)?
What is the market cap of Haoxi Health Technology (HAO)?
What does Haoxi Health Technology Limited do?
Where is Haoxi Health Technology Limited headquartered?
What industries does Haoxi Health Technology Limited serve?
What recent partnerships has Haoxi Health Technology Limited announced?
Which social media platforms does Haoxi use for advertising?
How does Haoxi optimize its advertising campaigns?
What is the value of the Framework Contract with Yiya Dental?
What is the Rebate Agreement with Yanling about?
How can I get more information about Haoxi Health Technology Limited?
Who is the CEO of Haoxi Health Technology Limited?
